Is there enough evidence for the use of immunoglobulins in either prevention or treatment of bacterial infection in preterm infants?

Studies so far revealed IVIG administration for the prevention of neonatal sepsis being safe resulting in a 3 to 4 percent reduction in nosocomial infections with no significant effect on mortality by meta-analyses. This marginal positive effect has to be discussed in the light of the costs and the values assigned to the clinical outcomes. There is not enough evidence for the use of immunoglobulins in the treatment of bacterial infection in preterm infants. IgM enriched IVIG might be beneficial for extremely low gestational age newborns but up to now meta-analyses do not support its general use in neonates.